Keymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt

EarningsKangyuedaNeutral

AI Analysis

Summary

Keymed Biosciences reported first-half 2026 financial results with total revenue of 617 million RMB, with core product Kangyueda generating 393 million RMB in revenue.

Financial Highlights

Revenue

617 million RMB

Importance:3/10

Sentiment:

0.00

earningsfinancial resultshalf-year resultsrevenueKangyueda

Related Companies

$CHHE

Read the original article

Published by PR Newswire Biotech on August 25, 2026 6:10 AM

Read Original